Prognostic factors for multiple myeloma in the era of novel agents

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Blade J ^a   Rosinol L ^a   Cibeira, M T ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BORTEZOMIB; DNA; LENALIDOMIDE; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER STAGING; CONFERENCE PAPER; DNA REPAIR; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; MOLECULAR GENETICS; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME; GENETICS; REVIEW;

HUMANS; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS;

EID: 53449085923     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn437     Document Type: Conference Paper

References (50)

1. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patents with multiple myeloma. Mayo Clin Proc 2003; 78: 21-23.
2. Bladé J, San Miguel JF, Fontanillas M et al. Increased convencional chemotherapy does not improve survival in multiple myeloma: Long-term results in two PETHEMA trials including 914 patients. Hematol J 2001; 2: 272-278.
3. The Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6633 patents from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
4. Kyle RA. Long-term survival in multiple myeloma. N Engl J Med 1983; 308: 314-316.
5. Alexanian RA. Ten-year survival in multiple myeloma. Arch Intern Med 1985; 145: 2073-2074.
6. Carbone PP, Kellerhouse LE, Gehan EA. Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med 1967; 42: 937-948.
7. Bladé J, Muñoz M, Fontanillas M et al. Treatment of multiple myeloma in elderly people: Long-term results in 178 patients. Age Ageing 1996; 25: 357-361.
8. Bladé J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93: 345-351.
9. Bladé J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med 1996; 156: 1463-1468.
10. Dimopoulos MA, Pouli A, Anagnostopoulos A et al. Macrofocal multiple myeloma in young patients: A distinct entity with favourable prognosis. Leuk Lymph 2006; 47: 1553-1559.
11. Ludwig H, Durie BGM, Bolejack V et al. Myeloma in patients under age 50 presents with more favourable features and shows better survival. An analysis of 10 459 patients from the International Myeloma Working Group. Blood 2008; 111: 4039-4047.
12. Bataille R, Grenier J, Sany J. Beta2-microglobulin in myeloma. Optimal use for staging, prognosis and treatment: A prospective study of 160 patents. Blood 1984; 63: 468-476.
13. San Miguel JF, Fonseca R, Greipp PR. Prognostic factors and classification for multiple myeloma: Contribution to clinical management. In Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds): Myeloma: Biology and Management, 3rd edition. Oxford: Saunders, Elsevier Inc. 2004; 189-199.
14. Witzig TE, Gertz MA, Lust JA et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma, Blood 1996; 88: 1780-1787.
15. Greipp PR, Raymond MN, Kyle RA et al. Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood 1985; 65: 305-310.
16. Greipp PR, Witzig TE, Gonchoroff NJ et al. Immunofluorescence labelling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987; 62: 969-977.
17. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693-1695.
18. Bladé J, Fernández-Llama P, Bosch F et al. Renal failure in multiple myeloma. Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889-1893.
19. Eleutherakis-Papaiakovou V, Bamias A, Gika D et al. Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance. Leuk Lymph 2007; 48: 337-341.
20. Bladé L, Rosinol L. Complications of multiple myeloma. Hematol Oncol Clin North Am 2007; 21: 1231-1246.
21. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
22. Merlini G, Waldesnström JG, Jayakar SD. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 1980; 55: 1011-1019.
23. Medical Research Working Party on Leukemia in Adults. Prognostic features on the third MRC myelomatosis trial. Br J Cancer 1980; 42: 831-840.
24. Cavo M, Galieni P, Zuffa E et al. Prognostic variables and clinical staging in multiple myeloma. Blood 1989; 74: 1778-1780.
25. Greipp PR, Katzman JA, O'Fallon WM et al. Value of beta2-microglobulin and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219-223.
26. Bladé J, Rozman C, Cervantes F et al. A new prognostic system for multiple myeloma based on easily available parameters. Br J Haematol 1989; 59: 113-118.
27. San Miguel JF, Sánchez I, González M. Prognostic factors and classification for multiple myeloma. Br J Cancer 1989; 59: 113-118.
28. San Miguel JF, Garcia Sanz R, González M et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448-455.
29. Greipp PR, San Miguel JF, Dude BGM et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
30. Fonseca R. Cytogenetics in multiple myeloma. In Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds): Myeloma: Biology and Management, 3rd edition. Oxford: Saunders, Elsevier Inc. 2004; 67-81.
31. Gutiérrez NC, Castellanos MV, Martín ML et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: T(4;14) is the most relevant prognostic factor, whereas Rb deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007; 21: 143-150.
32. Avet-Loisseau H, Attal M, Moreau P et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroup Francophone du Myelome. Blood 2007; 109: 3489-3495.
33. Shaughnessy JD, Zhan F, Burington BE et al. A validated expression signature of high-risk multiple myeloma is defined by dysregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284.
34. Zhan F, Yongsheng H, Colla S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028.
35. Carrasco R, Tonon G, Huang Y et al. High-resolution genomic profiles defines distinct clinicopathogenetic subgroups of multiple myeloma. Cancer Cell 2006; 4: 313-325.
36. Mateos MV, Hernández JM, Hernández MT et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 2006; 108: 2165-2172.
37. Rosiñol L, Oriol A, Mateos MV et al. A phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen prior to autologous stem cell transplantation in younger patients with multiple myeloma: Efficacy and clinical implications of tumour response kinetics. J Clin Oncol 2007; 25: 4452-4458.
38. Jagannath S, Richardson PG, Sonneveld P et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151-157.
39. Bladé J, López-Guillermo A, Bosch F et al. Impact of response to treatment on survival in multiple myeloma: Results in a series of 243 patients. Br J Haematol 1994; 88: 17-21.
40. Palmer M, Belch A, Brox L et al. Are the current criteria for response useful in the management of multiple myeloma? J Clin Oncol 1987; 5: 1373-1377.
41. Marmont F, Levis A, Falda M et al. Lack of correlation between objective response and death rate in multiple myeloma patients treated with melphalan and prednisone. Ann Oncol 1991; 2: 191-195.
42. Durie BGM, Jacobson J, Barlogie B et al. Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol 2004; 22: 1857-1863.
43. Lahuerta JJ, Martínez-López J, De la Serna J et al. Remission status by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438-446.
44. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043.
45. Bladé J, Esteve J, Rives S et al. High-dose therapy autotransplantation/intensification vs. continued standard chemotherapy in multiple myeloma in first remission. Results from a nonrandomized study from a single institution. Bone Marrow Transplant 2001; 26: 845-849.
46. Van de Velde HJH, Liu X, Chen G et al. Complete remission correlated with longterm survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399-1406.
47. Wang M, Delasalle S, Thomas S et al. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 2006; 108: 123a (Abstr 403).
48. Bladé J. Monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 355: 2765-2770.
49. Rosiñol L, Cibeira MT, Montoto S et al. Monoclonal gammopathy of undetermined significance: Predictors of malignant transformation and recognition of an evolving type characterized by a rising M-protein. Mayo Clin Proc 2007; 82: 428-434.
50. Kumar S, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.